STADA Ad hoc and press releases
Latest information
02/06/2012Ad hoc Release according §15 WpHG
STADA sells Irish production facility and thus continues to be in line with planning for the implementation of "STADA – build the future"
01/31/2012Ad hoc Update according §15 WpHG
STADA: Purchase of a branded product portfolio for the EU markets in Central Europe successfully concluded
01/31/2012Ad hoc Update according §15 WpHG
STADA: Purchase of a generics business in Switzerland successfully concluded
01/27/2012Ad hoc Update according §15 WpHG
STADA and Grünenthal agreed on the purchase of a branded product portfolio also for the EU markets in Central Europe at a lower purchase price
01/01/2012Ad hoc Update according §15 WpHG
STADA: Withdrawal from purchase of the Grünenthal branded product portfolio in Central Europe
12/30/2011Ad hoc Update according §15 WpHG
STADA: Purchase of a branded product portfolio in Eastern Europe as well as in the Middle East successfully concluded – Central Europe still open
12/01/2011Corporate News
STADA strengthens long-term refinancing with successful securing of promissory notes in the amount of EUR 400 million
11/23/2011Corporate News
STADA sales companies very successful in large-volume 7th AOK tender in the German generics market
11/10/2011Corporate News
STADA: Stabilization of business outlook in Serbia after letter of comfort from Serbian government
11/10/2011Corporate News
STADA 1-9/2011: Good development of sales and operating earnings – High burden on reported key earnings figures through one-time special effects – Confirmation of long-term growth targets
11/09/2011Ad hoc Update according §15 WpHG
STADA signs contract on the purchase of a generics business in Switzerland
10/31/2011Corporate News
STADA sales companies very successful in tenders for discount agreements with various German public health insurance organizations
09/21/2011Ad hoc Release according §15 WpHG
STADA: Increased risk of default on outstanding receivables from Serbian pharmaceutical wholesalers leads to burdening one-time special effects of approx. EUR 97 million before taxes
08/30/2011Corporate News
STADA and Richter cooperate for development of two biosimilar products for two monoclonal antibodies: Rituximab and Trastuzumab
08/11/2011Corporate News
STADA: Positive business development in H1/2011 – Increase of Group sales and all key earnings figures – Outlook remains positive for 2011/2012
08/01/2011Corporate News
STADA sales companies achieve very good results in fourth DAK tender in the German generics market
07/22/2011Ad hoc Update according §15 WpHG
STADA and Grünenthal sign contracts on the purchase of a branded product portfolio in Central and Eastern Europe as well as the Middle East
06/16/2011Corporate News
STADA AGM 2011: Executive Board continues to expect further growth in Group sales and earnings in 2011 and 2012
05/26/2011Corporate News
STADA acquires British branded product Cetraben® for GBP 30 million (approx. EUR 34.6 million)
05/19/2011Ad hoc Release according §15 WpHG
STADA negotiating the purchase of a generics business in Switzerland
05/12/2011Ad hoc Release according §15 WpHG
STADA and Grünenthal in exclusive negotiations on the purchase of a branded product portfolio in Central and Eastern Europe as well as the Middle East for approx. EUR 360 million
05/12/2011Corporate News
STADA: Positive business development in Q1/2011 – Increase of Group sales and all key earnings figures – Outlook remains positive for 2011/2012
05/11/2011Corporate News
STADA Group achieves strong result in 6th AOK tender in the German generics market
03/30/2011Corporate News
STADA: Good operating results confirm successful financial year 2010 – positive outlook for 2011/2012
02/28/2011Ad hoc Release according §15 WpHG
STADA: 2010 preliminary results confirm operationally successful year – dividend to amount to EUR 0.37 with unchanged distribution ratio – positive outlook for 2011/2012
